Table 2.
Baseline and end-apnea cerebrovascular variables
| Baseline |
Final 30 s |
|||
|---|---|---|---|---|
| Units | Placebo | Esmolol | Placebo | Esmolol |
| QICA, ml/min | 222.9 ± 33.5 | 201.5 ± 33.0 | 384.8 ± 77.1 | 347.6 ± 66.3 |
| QVA, ml/min | 74.3 ± 35.5 | 72.6 ± 38.7 | 144.5 ± 61.9 | 133.5 ± 57.3 (n = 6) |
| gCBF, ml/min | 583.6 ± 99.8 | 531.1 ± 88.2 | 935.2 ± 415.0 (n = 6) | 808.8 ± 373.1 (n = 6)† |
| MCAv, cm/s | 57.3 ± 11.5 | 54.8 ± 10.3 | 94.8 ± 11.8 | 92.2 ± 12.0 |
| PCAv, cm/s | 41.0 ± 13.4 (n = 8) | 39.2 ± 6.3 (n = 8) | 68.4 ± 17.6 (n = 8) | 64.6 ± 15.5 (n = 8) |
Values are means ± SE. QICA, internal carotid artery blood flow; ICAv, internal carotid artery blood velocity; DICA, internal carotid artery diameter; QVA, vertebral artery blood flow; VAv, vertebral artery blood velocity; DVA, vertebral artery diameter; gCBF, global cerebral blood flow; MCAv, middle cerebral artery blood velocity; PCAv, posterior artery blood velocity. As noted in methods, the values for QICA, QVA, and gCBF are based off of estimated velocity values combined with real diameter measurements.
†
Significant difference between placebo and esmolol, P < 0.05; n = 9 unless otherwise specified.